Validation of the criteria of transcatheter arterial chemoembolization failure or refractoriness in patients with advanced hepatocellular carcinoma proposed by the LCSGJ

Oncology (Switzerland)

Volumn 87, Issue , 2014, Pages 32-36

  Arizumi, Tadaaki ^a   Ueshima, Kazuomi ^a   Chishina, Hirokazu ^a   Kono, Masashi ^a   Takita, Masahiro ^a   Kitai, Satoshi ^a   Inoue, Tatsuo ^a   Yada, Norihisa ^a   Hagiwara, Satoru ^a   Minami, Yasunori ^a   Sakurai, Toshiharu ^a   Nishida, Naoshi ^a   Kudo, Masatoshi ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Hepatocellular carcinoma; Sorafenib; Transcatheter arterial chemoembolization failure

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; DECARBOXYPROTHROMBIN; SORAFENIB; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE;

ADVANCED CANCER; AGED; CANCER PROGNOSIS; CHEMOEMBOLIZATION; CHILD PUGH SCORE; CLINICAL ARTICLE; CONFERENCE PAPER; DRUG TREATMENT FAILURE; FEMALE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; LIVER CELL CARCINOMA; MALE; MONOTHERAPY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT RESPONSE; VALIDITY; ANALOGS AND DERIVATIVES; CANCER STAGING; CARCINOMA, HEPATOCELLULAR; COMPLICATION; HEPATIC ARTERY; HEPATITIS C; JAPAN; LIVER NEOPLASMS; MIDDLE AGED; PATHOLOGY; PROCEDURES; PROGNOSIS; REPRODUCIBILITY; RISK FACTOR; TREATMENT FAILURE; VALIDATION STUDY; VERY ELDERLY; VIROLOGY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; FEMALE; HEPATIC ARTERY; HEPATITIS C; HUMANS; JAPAN; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROGNOSIS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT FAILURE;

EID: 84922481973     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000368143     Document Type: Conference Paper

References (18)

1. Altekruse SF, McGlynn KA, Reichman ME: Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009; 27: 1485-1491.
2. El-Serag HB: Hepatocellular carcinoma. N Engl J Med 2011; 365: 1118-1127.
3. Kim do Y, Han KH: Epidemiology and surveillance of hepatocellular carcinoma. Liver Cancer 2012; 1: 2-14.
4. Parkin DM, Bray F, Ferlay J, Pisani P: Estimating the world cancer burden: Globocan 2000. I J Cancer 2001; 94: 153-156.
5. Moore MA, Sobue T: Cancer research and control activities in Japan: contributions to international efforts. Asian Pac J Cancer Prev 2009; 10: 183-200.
6. Bruix J, Sala M, Llovet JM: Chemoembolization for hepatocellular carcinoma. Gastroenterology 2004; 127:S179-S188.
7. Bruix J, Sherman M; American Association for the Study of Liver Diseases: Management of hepatocellular carcinoma: An update. Hepatology 2011; 53: 1020-1022.
8. Llovet JM, Ducreux M, et al: EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56: 908-943.
9. Kudo M, Izumi N, Kokudo N, Matsui O, Sakamoto M, Nakashima O, Kojiro M, Makuuchi M: Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig Dis 2011; 29: 339-364.
10. Lencioni R: Chemoembolization for hepatocellular carcinoma. Semin Oncol 2012; 39: 503-509.
11. Lencioni R: Chemoembolization in patients with hepatocellular carcinoma. Liver Cancer 2012; 1: 41-50.
12. Lin S, Hoffmann K, Schemmer P: Treatment of hepatocellular carcinoma: A systematic review. Liver Cancer 2012; 1: 144-158.
13. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390.
14. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34.
15. Kudo M: Treatment of advanced hepatocellular carcinoma with emphasis on hepatic arterial infusion chemotherapy and molecular targeted therapy. Liver Cancer 2012; 1: 62-70.
16. Kudo M, Matsui O, Izumi N, Iijima H, Kadoya M, Imai Y, Okusaka T, Miyayama S, Tsuchiya K, Ueshima K, Hiraoka A, Ikeda M, Ogasawara S, Yamashita T, Minami T, Yamakado K; Liver Cancer Study Group of Japan: JSH consensus-based clinical practice guideline for the management of hepatocellular carcinoma: 2014 update by the Liver Cancer Study Group of Japan. Liver Cancer 2014;3:458-468.
17. Raoul JL, Sangro B, Forner A, Mazzaferro V, Piscaglia F, Bolondi L, Lencioni R: Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: Available evidence and expert opinion on the use of transarterial chemoembolization. Cancer Treat Rev 2011; 37: 212-220.
18. Raoul JL, Gilabert M, Piana G: How to define transarterial chemoembolization failure or refractoriness: A European perspective. Liver Cancer 2014; 3: 119-124.